Substance / Medication

Etelcalcetide

Overview

Active Ingredient
etelcalcetide
RxNorm CUI
1876119

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients.
Dörr Katharina, Reindl-Schwaighofer Roman, Lorenz Matthias et al. · Cardiorenal Med · 2023
PMID: 37729887RCTFull text (PMC)
Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy.
Marn Pernat Andreja, Pajek Jernej, Buturović-Ponikvar Jadranka · Clin Nephrol · 2025
PMID: 41307414Observational
Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis.
Hashimoto Yusaku, Kato Sawako, Kuro-O Makoto et al. · Nephrology (Carlton) · 2022
PMID: 35749253Observational
Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Shoji Tetsuo, Nakatani Shinya, Kabata Daijiro et al. · Clin J Am Soc Nephrol · 2021
PMID: 33685864ObservationalFull text (PMC)
Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis.
Dörr Katharina, Kammer Michael, Reindl-Schwaighofer Roman et al. · Circ Res · 2021
PMID: 33825489Observational
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky David A, Chertow Glenn M, Cheng Sunfa et al. · Nephrol Dial Transplant · 2020
PMID: 30859218ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Etelcalcetide (substance)
SNOMED CT
723539000
UMLS CUI
C3713906
RxNorm CUI
1876119

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.